C WorldWide Group Holding A S Sells 20,000 Shares of Natera, Inc. $NTRA

C WorldWide Group Holding A S cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 14.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 118,000 shares of the medical research company’s stock after selling 20,000 shares during the quarter. Natera makes up approximately 0.8% of C WorldWide Group Holding A S’s portfolio, making the stock its 20th largest holding. C WorldWide Group Holding A S owned 0.08% of Natera worth $32,031,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Trust Co. of Vermont purchased a new stake in shares of Natera during the 2nd quarter valued at approximately $26,000. Reflection Asset Management bought a new position in shares of Natera in the fourth quarter worth $29,000. Elevation Wealth Partners LLC purchased a new position in shares of Natera in the second quarter valued at $30,000. Palladiem LLC bought a new stake in shares of Natera during the 4th quarter valued at $31,000. Finally, Horizon Investments LLC purchased a new stake in Natera during the 3rd quarter worth about $32,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

Natera stock opened at $324.14 on Wednesday. Natera, Inc. has a fifty-two week low of $157.43 and a fifty-two week high of $343.18. The stock has a market cap of $46.72 billion, a P/E ratio of -238.34 and a beta of 1.54. The firm’s fifty day moving average price is $294.79 and its 200-day moving average price is $239.44.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.74) EPS. On average, analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

Insider Buying and Selling at Natera

In other Natera news, Director Herm Rosenman sold 16,530 shares of Natera stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the transaction, the director directly owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 15,160 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the sale, the insider owned 110,859 shares of the company’s stock, valued at approximately $36,238,698.51. The trade was a 12.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 71,206 shares of company stock valued at $19,944,069. 5.05% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several analyst reports. Citigroup upped their price target on Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Piper Sandler upped their target price on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. TD Cowen increased their target price on shares of Natera from $325.00 to $340.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Barclays restated an “overweight” rating and set a $340.00 price target on shares of Natera in a research report on Friday, August 7th. Finally, Wells Fargo & Company boosted their target price on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $322.50.

Natera Profile

Natera, Inc is a diagnostic company that develops and commercializes molecular testing services based on cell-free DNA and other genetic technologies. The company’s tests are designed to help clinicians assess genetic and reproductive health, monitor organ transplants, and detect and track cancer.

Its principal products include Panorama, a noninvasive prenatal screening test; Horizon, a carrier screening test; Signatera, a personalized circulating tumor DNA test used in cancer monitoring; and Prospera, a molecular test intended to help assess the risk of organ transplant rejection.